The Effectiveness of Dialectical Behavioral Group Psychotherapy Compared to Supportive Individual Psychotherapy In Patients With Borderline Personality Disorder: A Study on Therapeutic Alliance, Depression, Cognitive Function, Impulsivity, Suicide Risk, BDNF Levels, NFkB Levels, SOD Levels (DBT BPD)

March 4, 2026 updated by: Natalia Dewi Wardani, MD
In the context of therapy for Borderline Personality Disorder, our department had conduct a study titled "The Effectiveness of Dialectical Behavioral Group Psychotherapy Compared to Supportive Individual Psychotherapy in Patients with Borderline Personality Disorder: A Study of Therapeutic Alliance, Depression, Cognitive Function, Impulsivity, Suicide Risk, BDNF Levels, NFkB Levels, SOD Levels."

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Psychotherapy for Borderline Personality Disorder provided weekly for 13 weeks. Patients have given a logbooks. Researchers monitored patients weekly by telephone and monitor them during outpatient visits in the second, fourth, sixth, eighth, and twelfth weeks. Blood samples were taken before and 13 weeks after treatment. During the study, patients were advised not to consume any medications or herbal remedies outside of those prescribed by the doctor and recorded in the study.

Study Type

Interventional

Enrollment (Actual)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Indonesia
    • Central Java
      • Semarang, Central Java, Indonesia, 50275
        • Medical Faculty Diponegoro University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged 18-60 years old
  • Diagnosed with Borderline Personality Disorder based on the Structured Clinical Interview for DSM-V Axis II Disorders (SCID-II)
  • Junior high school education or higher
  • Patients willing to participate in the study.

Exclusion Criteria:

  • Taking immunosuppressive drugs since one week before the study.
  • Based on interviews or medical records, there is no history of post-stroke, epilepsy, or diabetes mellitus.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: DBT group psychotherapy
13 weeks, one session per week. Each week, 2-hour dialectical therapy group session for 5 patients per group.
Behavioral: DBT group psychotherapy
13 weeks, one session per week. Each week, one 2-hour dialectical therapy group session for 5 patients in a group.
Active Comparator: Suportive psychotherapy
13 weeks, one session per week. Each week, one 30-minute session of individual supportive psychotherapy.
Behavioral: Supportive Psychotherapy
13 weeks, one session per week. Each week, one 30-minute session of individual supportive psychotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
impulsivity with Barrat Impulsiveness Scale (BIS11)
Time Frame: 13 weeks
Barrat Impulsiveness Scale (BIS11) score, interval, Higher scores indicate greater impulsivity, with 30-51 indicating low, 52-71 average, and 72+ high impulsivity.
13 weeks
Suicide Risk with Columbia Suicide Severity Rating Scale (CSSRS)
Time Frame: 13 weeks
Columbia Suicide Severity Rating Scale (CSSRS) score, interval, Any "Yes" answer to behavior or ideation requires further clinical assessment.
13 weeks
Therapeutic Alliances with California Psychotherapy Alliance Scales (CALPAS)
Time Frame: 13 weeks
California Psychotherapy Alliance Scales (CALPAS) score. A higher CALPAS (California Psychotherapy Alliance Scale) score indicates a stronger, more positive therapeutic alliance between a patient and their therapist. The California Psychotherapy Alliance Scale (CALPAS) uses a 7-point Likert scale for its 24 items, ranging from 1 ("not at all") to 7 ("very much so"). Minimum score 24 and maximum score 168.
13 weeks
Depression with GRID Hamilton Depression Rating Scale (GRID HAM-D)
Time Frame: 13 weeks

GRID Hamilton Depression Rating Scale (GRID HAM-D) score, interval, higher total scores indicating greater severity of depression.

Minimum Score: 0 (No depression) Maximum Score: 52 (Severe depression)
13 weeks
cognitive function with Montreal Cognitive Assesment versi Indonesia (MoCA-Ina)
Time Frame: 13 weeks
Montreal Cognitive Assesment Indonesian version (MoCA-Ina) score, interval. A 30-point screening tool validated to detect mild cognitive impairment (MCI) and dementia in Indonesia, with a score of 26 or higher considered normal.
13 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NFkB Levels in ng/ml
Time Frame: 13 weeks
ratio scale, nanogram/mililiter
13 weeks
BDNF level in pg/ml
Time Frame: 13 weeks
BDNF level in picogram/mililiter, ratio scale
13 weeks
SOD levels in ng/ml
Time Frame: 13 weeks
ratio scale, nanogram/mililiter
13 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Natalia Dewi Wardani, MD

Collaborators

Faculty of Medicine University of Diponegoro, Indonesia

Investigators

  • Study Chair: M.I. Widiastuti MIW Widiastuti, Prof. dr.PAK(K), Sp.S(K), M.Sc, Medical Faculty Diponegoro University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 16, 2021

Primary Completion (Actual)

December 16, 2022

Study Completion (Actual)

November 5, 2023

Study Registration Dates

First Submitted

February 21, 2026

First Submitted That Met QC Criteria

February 26, 2026

First Posted (Actual)

March 4, 2026

Study Record Updates

Last Update Posted (Actual)

March 6, 2026

Last Update Submitted That Met QC Criteria

March 4, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 976/EC/KEPK-RSDK/2021
  • 247/UN7.5.4/HK/2022 (Other Grant/Funding Number: Medical Faculty Diponegoro University Grant 2022)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The data are not publicly available due to privacy or ethical restrictions. The dataset involves sensitive information from minors regarding mental health, and sharing it publicly would compromise participant confidentiality as per the ethical approval obtained.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Borderline Personality Disorder (BPD)

Clinical Trials on DBT group psychotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe